---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-24-000155"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2024-08-30T23:59:59+00:00"
generated_at: "2026-05-31T06:46:15.752329+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions gets FDA approval for ACAM2000 mpox indication

## Summary
- FDA approved sBLA for ACAM2000 to prevent mpox in high-risk individuals based on animal study safety/efficacy data.
- ACAM2000 is a single-dose, percutaneously administered smallpox vaccine first approved in 2007.
- Emergent will donate 50,000 doses for potential deployment across impacted Central African countries.
- Company filed Expression of Interest with WHO for Emergency Use Listing amid mpox outbreak.

## SEC filing metadata
- accession: 0001367644-24-000155
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2024-08-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000155/0001367644-24-000155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000155/ebs-20240829.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-24-000155
- JSON: https://secwatch.observer/filing/0001367644-24-000155.json
- Plain text: https://secwatch.observer/filing/0001367644-24-000155.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.